bioAffinity Technologies, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Upon issuance, the Mexican patent application will protect the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer
bioAffinity posts softer first-quarter 2026 results after exiting lower-margin pathology services, though CyPath Lung adoption and clinical-trial progress gain traction.
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath® Lung diagnostic test
bioAffinity Technologies has prioritized CyPath® Lung as its core commercial focus, aligning resources to accelerate adoption and scale. Growth has been driven by:Expansion of ordering physician sitesIncreased
CyPath® Lung unit sales in April increased nearly 300% compared to April 2025Increasing unit sales for CyPath® Lung continues first quarter 2026 trend of accelerating adoption and clinical...
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. This section presents management's perspective on our financial condition and results of...
bioAffinity Technologies Inc: BioAffinity Technologies Inc - Q1 2026 net loss $3.6 million or $0.81 per share BioAffinity Technologies Inc - total consolidated revenue decreases 27% to $1.4...
bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(2.70) by 70 percent. This is a 83.13 percent increase over losses of $(4.80) per share
CyPath® Lung cancer diagnostic unit sales rise 146% year-over-yearGrowth expected to accelerate throughout 2026 as planned commercial initiatives seek to drive increasing awareness of CyPath®...
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Collaboration with nation’s largest military medical center focuses on bioAffinity Technologies’ pipeline of solutions to address debilitating respiratory diseasesStudy to explore the potential...
Collaboration with nation's largest military medical center focuses on bioAffinity Technologies' pipeline of solutions to address debilitating respiratory diseasesStudy to explore the potential for proprietary flow
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
SAN ANTONIO - bioAffinity Technologies, Inc. , a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, released a new clinical case study illustrating how...
Standard-of-care imaging and risk models indicated cancer after lung screening revealed 30-millimeter pulmonary noduleCyPath® Lung test affirmed physician’s assessment that the nodule could be...
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis April 8,...
SAN ANTONIO, April 07, 2026--CyPath Lung, bioAffinity Technologies' noninvasive test for lung cancer, will be featured at the Cleveland Clinic's annual lung cancer symposium.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 14.4K | $55.10K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2025-11-14 | -2.70 | -4.74 | -75.56% |
| 2025-08-14 | -3.00 | -5.10 | -70.00% |
| 2025-05-15 | -4.80 | -4.80 | — |
| 2025-03-31 | -4.20 | -6.30 | -50.00% |
| 2024-11-14 | -4.50 | -4.80 | -6.67% |
| 2024-08-14 | -5.10 | -5.70 | -11.76% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BIAF | -23.74% | +75.60% | +41.53% | -80.12% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -26.71% | +80.24% | +44.97% | -92.81% |